Validation Archives

Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study
Gallery
Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study

Validation of a Clinicopathologic and Gene Expression Model for Predicting Sentinel Node Metastasis in Melanoma: A Multicenter Danish Cohort Study

Weitemeyer et al., Journal of Surgical Oncology.

Joel Wolter2025-07-23T16:42:11-05:00July 7, 2025|

Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.
Gallery
Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.

Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis.

Amaral et al., 2025. ASCO Conference.

Joel Wolter2025-07-24T13:24:26-05:00May 30, 2025|

Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients
Gallery
Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients

Assessing risk of nodal metastasis and relapse-free survival by CP-GEP (Merlin™ Test) in a single-center retrospective case series of stage pT1a-4b cN0M0 melanoma patients

Kessels et al., 2025. World Congress of Melanoma.

Joel Wolter2025-07-24T14:06:12-05:00March 4, 2025|

Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Gallery
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy

Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy

Amaral et al., 2025. World Congress of Melanoma.

Joel Wolter2025-07-24T13:54:03-05:00March 4, 2025|

Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)
Gallery
Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)

Clinicopathologic and gene expression profile (CP-GEP) is a biomarker for outcome in patients with melanoma eligible for sentinel lymph node biopsy (SLNB)

Zijlker et al., 2025. World Congress of Melanoma.

Joel Wolter2025-07-24T13:48:35-05:00March 4, 2025|

Using CP-GEP model (Merlin Assay) to stratify melanoma patients on long-term survival in a multi-continent cohort study
Gallery
Using CP-GEP model (Merlin Assay) to stratify melanoma patients on long-term survival in a multi-continent cohort study

Using CP-GEP model (Merlin Assay) to stratify melanoma patients on long-term survival in a multi-continent cohort study

Utikal et al., 2025. World Congress of Melanoma.

Joel Wolter2025-07-24T13:41:08-05:00March 4, 2025|

CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis
Gallery
CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis

CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis

W. Yu et al. 2024. SMR Conference.

Joel Wolter2025-03-25T02:47:08-05:00October 10, 2024|

Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.
Gallery
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.

Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: a H&N subgroup analysis.

Amaral et al., 2024. ASCO conference.

Joel Wolter2025-03-25T02:58:48-05:00May 31, 2024|

Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy
Gallery
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy

Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy

Amaral et al., American Society of Clinical Oncology

Joel Wolter2025-03-25T02:50:09-05:00May 31, 2024|

Predictive Performance of the Clinicopathologic Gene Expression Profile (CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis.
Gallery
Predictive Performance of the Clinicopathologic Gene Expression Profile (CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis.

Predictive Performance of the Clinicopathologic Gene Expression Profile (CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis.

T. Wong et. al., 2024. AMC Congress

Joel Wolter2025-03-25T02:51:32-05:00May 25, 2024|